Evidence map›Paper›PMID 31096854›Full record

ReviewTherapeutic advances in respiratory disease

Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base.

Anthony D D'Urzo, Dave Singh, James F Donohue, Kenneth R Chapman

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. An Add-On Treatment for Moderate COPD with Squill-Oxymel (a Traditional Formulation fromEvidence-based complementary and alternative medicine : eCAM · 2022
    Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Anthony D D'UrzoDepartment of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON 12354, Canada.ORCID 0000-0003-2781-2802
Dave SinghMedicines Evaluation Unit, Manchester University NHS Foundations Trust, Manchester, UK.
James F DonohueDivision of Pulmonary Diseases and Critical Care Medicine, University of North Carolina Pulmonary Critical Medicine, Chapel Hill, NC, USA.
Kenneth R ChapmanAsthma and Airway Center, Toronto Western Hospital, Toronto, ON, Canada.
Toronto Western Hospital · CAUniversity of Manchester · GBUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aclidinium bromide/formoterol fumarate (AB/FF) 400/12 µg is a twice-daily long-acting muscarinic receptor antagonist and long-acting β

Indexed as

Adrenergic beta-2 Receptor AgonistsAdultBronchodilator AgentsDrug CombinationsFormoterol FumarateHumansMuscarinic AntagonistsPulmonary Disease, Chronic ObstructiveQuality of LifeSeverity of Illness IndexTropanesaclidinium bromideAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsDrug CombinationsFormoterol FumarateMuscarinic AntagonistsTropanesaclidiniumbronchodilatorsCOPDformoterollong-acting muscarinic antagonistlong-acting β-agonistmaintenance treatment

Identifiers

PMID31096854
PMCPMC6535700
OpenAlexW2945060451

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.